In order to investigate the endogenous occurrence of vasopressin fragments that have previously been found to be generated in vitro by brain peptidases and to have highly potent central activity, extracts of hypothalamus, hippocampus and the pituitary gland were fractionated by high pressure liquid chromatography and analyzed by radioimmunoassay systems with different specificities. Substances that were immunologically and chromatographically similar to synthetic C-terminal vasopressin fragments were detected in brain tissue in different amounts, but were virtually absent in the pituitary gland. It is suggested that these components may represent endogenous vasopressin metabolites. The preferential presence in brain supports a selectively central function of these peptides.
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Arginine-vasopressin (AVPI_9) is a hormone in the peripheral circulation and neuropeptide in the brain affecting a number of central processesl,5, 6J°,11. Unlike the exclusively hormonal activities of AVPI_9, the central activities do not require the entire nonapeptide structure; several synthetic fragments of AVPI_ 9 have central activities by themselves 6. Recently, a number of AVP fragments that were generated by in vitro proteolysis of AVPI_ 9 by synaptic membranes have been characterized2,12. One of these peptides, [pGlu4,Cyt 6] AVP4_ 9, and its des-glycinamide derivative were a thousand times more potent than AVPI_ 9 in affecting behavior, but lacked vasopressor activity3, 6. These findings suggested that such AVP fragments possessing selectively central activity might have a role as neuropeptides in the brain. Here we report the presence of peptides that resemble AVP fragments in brain as characterized in high-pressure liquid chromatography in combination with two radioimmunoassays using antisera of different specificity. It is shown that the hippocampus, a terminal area of the central vasopressinergic system, is relatively rich in these materials, whereas the pituitary gland containing terminals for peripheral AVP is virtually devoid of them. It is suggested that these substances represent metabolites of AVP that are preferentially generated in brain. Such AVP metabolites might be the active principles for some of the central actions of AVP.
Tissue was used from male Wistar rats (180-200 g) which had been handled for 5 days prior to decapitation. The whole pituitary gland was taken and the hypothalamus and hippocampus were dissected from the brain s . Tissues were immediately frozen on dry ice and extracted after boiling in 1 M acetic acid and subsequent cooling to 0 °C by homogenization using a Branson sonifier. Particulate material was removed by centrifugation at 20,000 gay for 30 min and the clear supernatants were lyophilized. Subsequently, samples were reconstituted in a small volume of 0.05 M acetic acid and made up to 1.0 ml with starting HPLC solvent. Fractionation of extracts was carried out by reverse phase HPLC with ammonium acetate and methanol in the mobile phase 2,12. Fractions were collected and prepared for radioimmunoassay determination (for details see legend to Fig. 1 ). The radioimmunoassay systems employed antiserum W1A or antiserum W4E, [:25I]AVPl_9 as tracer and synthetic AVP:_ 9 as a standard. Procedures have been previously described 7. Crossreaction of antiserum W1A
